We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04639310
Previous Study | Return to List | Next Study

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04639310
Recruitment Status : Recruiting
First Posted : November 20, 2020
Last Update Posted : November 10, 2022
Sponsor:
Information provided by (Responsible Party):
Xenon Pharmaceuticals Inc.

Brief Summary:
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).

Condition or disease Intervention/treatment Phase
Epilepsy Epilepsy in Children Epilepsy; Seizure Disease Brain Diseases Central Nervous System Diseases Nervous System Diseases Epileptic Syndromes Drug: XEN496 Drug: Placebo Phase 3

Detailed Description:
The EPIK Phase 3 clinical trial is designed as a randomized, double-blind, placebo-controlled, multicenter study targeting to enroll approximately 40 pediatric subjects (aged from 1 month to less than 6 years) with documented genetic evidence consistent with a diagnosis of KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE). After screening, subjects will enter a baseline period before being randomized to receive either XEN496 (ezogabine) or placebo, added to their existing antiseizure medications (ASMs), for 12 weeks (maintenance), once a titration period of up to 24 days is complete. At the end of the maintenance phase, eligible subjects will have the opportunity to qualify for and participate in the separate open-label extension (OLE) study and receive XEN496 or, should they choose to exit the study, will undergo a dose taper period of up to 15 days and 4-week follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy
Actual Study Start Date : March 29, 2021
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy Seizures
Drug Information available for: Ezogabine

Arm Intervention/treatment
Experimental: XEN496
24-day dose titration period to a top dose of 21 mg/kg/day. Subjects continue at the top dose, or the highest tolerated dose up to the top dose, for 12-week maintenance period. If the subject does not immediately enter into the separate open-label extension (OLE) study, the maintenance period will be followed by a 15-day taper period.
Drug: XEN496
XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
Other Names:
  • ezogabine
  • retigabine

Placebo Comparator: Placebo
To maintain the blinded aspect of the study, subjects will be titrated on placebo over the 24-day period and remain at this dose for the 12-week maintenance period. If the subject does not immediately enter into the separate OLE study, the maintenance period will be followed by a 15-day taper period.
Drug: Placebo
Placebo sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.




Primary Outcome Measures :
  1. Percent change from baseline in monthly (28 day) countable motor seizure frequency during the blinded treatment period [ Time Frame: From baseline to the end of the double-blind, 12 week treatment period (maintenance) ]
    Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity


Secondary Outcome Measures :
  1. Proportion of subjects with ≥50 percent reduction in monthly (28 day) seizure frequency [ Time Frame: From baseline to the end of the double-blind, 12 week treatment period (maintenance) ]
    Parent/caregiver seizure diary record will be used to assess frequency, type and duration

  2. Caregiver Global Impression of Change (CaGI-C) scores for the subject's overall condition and for seizures [ Time Frame: Study Days 24, 67, 88 and 109 ]
    CaGI-C scale is a caregiver-reported assessment for the subject's overall condition and for seizures. Responses to the CaGI-C questionnaire are to be rated on a 7 item Likert scale ranging from very much improved to very much worse.

  3. Change from baseline in the Caregiver Global Impression of Severity (CaGI-S) for the subject's overall condition and for seizures [ Time Frame: Study Days 1, 24, 67, 88 and 109 ]
    CaGI-S scale is Caregiver-reported assessment of the severity of the subject's seizures and overall condition over the previous 7 days. Responses to the CaGI-S questionnaire are to be rated on a 5 item Likert scale ranging from none to very severe.


Other Outcome Measures:
  1. Assess the safety and tolerability of XEN496 (e.g., adverse events) in pediatric subjects with KCNQ2-DEE [ Time Frame: From screening through to the end of the study (maintenance phase for those continuing into the OLE) or Day 151 for those exiting the study ]
    To assess adverse events as criteria for safety and tolerability



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Month to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects aged from 1 month to less than 6 years, with a body weight of ≥3.0 kg at screening.
  • Documented evidence of a genetic test result from an appropriately accredited laboratory, consistent with a diagnosis of KCNQ2-DEE (pathogenic, likely pathogenic, variant of unknown significance, or inconclusive but unlikely to support an alternate diagnosis).
  • Seizure onset within 2 weeks after birth and EEG and documented clinical history consistent with KCNQ2-DEE.
  • Magnetic resonance imaging has been performed and is without evidence of structural abnormalities, including but not limited to, hypoxia, hypoxia-ischemia, ischemia (arterial or venous), stroke, sinovenous thrombosis, intracranial hemorrhage, or focal or global brain malformation. Brain MRI changes that are described as being associated with the KCNQ2-DEE and presumed to be secondary to the disease itself, will not be exclusionary.
  • Must have had focal tonic or other countable motor seizures in the 28 days prior to screening.
  • Taking 1 and no more than 4 concomitant antiseizure medications (ASMs). All doses must be stable for at least 1 week prior to screening and expected to be maintained throughout the duration of the study.
  • Vagal nerve stimulation (VNS) is allowed and will not be counted as a concomitant ASM. The VNS device must be implanted for at least 6 months before screening, and the device settings must be stable for at least 6 weeks prior to screening and throughout the duration of the study. Use of the VNS device magnet is allowed.
  • Ketogenic diet is allowed and will not be counted as a concomitant ASM. Must must be on a stable dietary regimen that produces ketosis for at least 6 weeks prior to screening, and expected to be maintained throughout the study.
  • Additional inclusion criteria apply, and will be assessed by the study team.

Exclusion Criteria:

  • Presence of a pathogenic or likely pathogenic variant in an additional gene associated with other epilepsy syndromes. (Variants in other epilepsy-associated genes that are not known to be pathogenic or are not likely to be pathogenic based upon adjudication review will not be a basis for exclusion.)
  • Presence of a known gain-of-function variant in the KCNQ2 gene, or clinical characteristics consistent with previously reported pathogenic gain-of-function variants in the KCNQ2 gene.
  • Seizures secondary to infection, neoplasia, demyelinating disease, degenerative neurological disease, or Central nervous system (CNS) disease deemed progressive, metabolic illness, or progressive degenerative disease.
  • Confirmed diagnosis of infantile spasms within the past month prior to screening.
  • History or presence of any significant medical or surgical condition or uncontrolled medical illness at screening including, but not limited to, cardiovascular, gastrointestinal, hematologic, hepatic, ocular, pulmonary, renal, or urogenital systems, or other conditions that would not justify the subject's participation in the study, as determined by the investigator's risk benefit assessment.
  • QT interval corrected for heart rate by Fridericia's formula (QTcF) of >440 msec. In addition, subjects with a history of arrhythmia, prolonged QT, heart disease or subjects taking medications known to increase the QT interval.
  • History of hyperbilirubinemia, which lasts longer than 1 week will require exclusion of hepatic disease before entering the study.
  • History of bilirubin-induced neurological dysfunction.
  • Current disturbance of micturition or known urinary obstructions or history of bladder or urinary dysfunction including abnormal post-void residual bladder ultrasound, vesicoureteral reflux, urinary retention, or required urinary catheterization in the preceding 6 months.
  • Known to have a terminal illness.
  • Any clinically significant laboratory abnormalities or clinically significant abnormalities on pre-study physical examination, vital signs, or ECG that in the judgment of the investigator indicates a medical problem that would preclude study participation.
  • Planned to begin a ketogenic or other specialized dietary therapy during the study.
  • Caregiver history of chronic noncompliance with their child's prescribed drug regimens that has not been corrected.
  • Exposure to any other investigational drug or device within 5 half-lives or 30 days prior to screening, whichever is longer or plans to participate in another drug or device trial at any time during the study.
  • Concurrent enrollment in any other type of medical research judged by the investigator not to be scientifically or medically compatible with this study.
  • Using felbamate presenting with clinically significant abnormalities and/or hepatic dysfunction during felbamate treatment, and subjects who have taken felbamate for less than 6 months prior to screening.
  • Currently taking adrenocorticotropic hormone.
  • Did not tolerate ezogabine when taken previously.
  • Subjects with a known hypersensitivity to ezogabine or any of the excipients in the study drug.
  • Other exclusion criteria apply, and will be assessed by the study team.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04639310


Contacts
Layout table for location contacts
Contact: Xenon Pharmaceuticals Inc. 1-604-484-3300 XenonCares@xenon-pharma.com

Locations
Show Show 17 study locations
Sponsors and Collaborators
Xenon Pharmaceuticals Inc.
Investigators
Layout table for investigator information
Study Director: Study Director Xenon Pharmaceuticals Inc.
Layout table for additonal information
Responsible Party: Xenon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT04639310    
Other Study ID Numbers: XPF-009-301
2020-002396-35 ( EudraCT Number )
First Posted: November 20, 2020    Key Record Dates
Last Update Posted: November 10, 2022
Last Verified: November 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Xenon Pharmaceuticals Inc.:
XEN496
Ezogabine
Retigabine
Encephalopathy
Seizure
KCNQ2
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Seizures
Brain Diseases
Nervous System Diseases
Central Nervous System Diseases
Epileptic Syndromes
Neurologic Manifestations
Ezogabine
Anticonvulsants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action